Rao N V S Mamidi
Overview
Explore the profile of Rao N V S Mamidi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
266
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Snyder L, Damle R, Patel S, Bohrer J, Fiorella A, Driscoll J, et al.
Mol Cancer Ther
. 2022 May;
21(7):1115-1124.
PMID: 35499386
Patients with prostate cancer whose tumors bear deleterious mutations in DNA-repair pathways often respond to PARP inhibitors. Studies were conducted to compare the activity of several PARP inhibitors in vitro...
2.
de Zwart L, Snoeys J, Jacobs F, Li L, Poggesi I, Verboven P, et al.
CPT Pharmacometrics Syst Pharmacol
. 2021 Jul;
10(9):1107-1118.
PMID: 34273250
Erdafitinib is a potent oral pan-fibroblast growth factor receptor inhibitor being developed as oncology drug for patients with alterations in the fibroblast growth factor receptor pathway. Erdafitinib binds preferentially to...
3.
Saad F, Chi K, Shore N, Graff J, Posadas E, Lattouf J, et al.
Cancer Chemother Pharmacol
. 2021 Mar;
88(1):25-37.
PMID: 33754187
Purpose: To assess the safety and pharmacokinetics and determine the recommended phase 2 dose (RP2D) of niraparib with apalutamide or abiraterone acetate plus prednisone (AAP) in patients with metastatic castration-resistant...
4.
Mamidi R, Devineni D, Sun D, Yavin Y, Rosenthal N
Ann Intern Med
. 2021 Mar;
174(3):431-432.
PMID: 33721528
No abstract available.
5.
Scheers E, Borgmans C, Keung C, Bohets H, Wynant I, Poggesi I, et al.
Xenobiotica
. 2020 Sep;
51(2):177-193.
PMID: 32902324
This article describes biotransformation and disposition of erdafitinib following single oral dose of H-erdafitinib and C-erdafitinib to intact and bile duct-cannulated (BC) rats (4 mg/kg), H-erdafitinib to intact dogs (0.25 ...
6.
Poggesi I, Li L, Jiao J, Hellemans P, Rasschaert F, de Zwart L, et al.
Eur J Drug Metab Pharmacokinet
. 2019 Nov;
45(1):101-111.
PMID: 31673875
Background And Objectives: Erdafitinib, an oral selective pan-fibroblast growth factor receptor (FGFR) kinase inhibitor, is primarily metabolized by cytochrome P450 (CYP) 2C9 and 3A4. The aim of this phase 1...
7.
Jonghe S, Johnson M, Mamidi R, Vinken P, Feyen B, Lammens G, et al.
Chem Biol Interact
. 2017 Sep;
277:85-90.
PMID: 28916336
During preclinical development of canagliflozin, an SGLT2 inhibitor, treatment-related pheochromocytomas, renal tubular tumors (RTT), and testicular Leydig cell tumors were reported in the 2-year rat toxicology study. In a previous...
8.
Mamidi R, Dallas S, Sensenhauser C, Lim H, Scheers E, Verboven P, et al.
Br J Clin Pharmacol
. 2016 Nov;
83(5):1082-1096.
PMID: 27862160
Aims: Canagliflozin is a recently approved drug for use in the treatment of type 2 diabetes. The potential for canagliflozin to cause clinical drug-drug interactions (DDIs) was assessed. Methods: DDI...
9.
Devineni D, Manitpisitkul P, Murphy J, Skee D, Wajs E, Mamidi R, et al.
Clin Pharmacol Drug Dev
. 2016 May;
4(3):226-36.
PMID: 27140803
Drug-drug interactions between canagliflozin, a sodium glucose co-transporter 2 inhibitor, and glyburide, metformin, and simvastatin were evaluated in three phase-1 studies in healthy participants. In these open-label, fixed sequence studies,...
10.
Devineni D, Murphy J, Wang S, Stieltjes H, Rothenberg P, Scheers E, et al.
Clin Pharmacol Drug Dev
. 2016 May;
4(4):295-304.
PMID: 27136910
Absolute oral bioavailability of canagliflozin was assessed by simultaneous oral administration with intravenous [(14) C]-canagliflozin microdose infusion in nine healthy men. Pharmacokinetics of canagliflozin, [(14) C]-canagliflozin, and total radioactivity, and...